Oncology Products with Purpose
Development
Shorla Oncology’s innovative oncology pipeline addresses drug shortages and treatments inadequate for the target population by reinventing & rethinking existing oncology medications with the goal of improving the lives of patients around the globe.
Our development strategy of rethinking approved pharmaceuticals primarily through the 505 (b)(2) regulatory pathway provides a focused strategy that can dramatically reduce clinical burden, cost & risk while maximizing speed to market.
At Shorla Oncology we have built a flexible go-to-market strategy, enabling us to commercialize our oncology portfolio in a cost-efficient manner coupling in-house expertise and market leading external commercial partners. With this highly adaptable team & infrastructure we can remain flexible and assess the optimal commercialization strategy on a case-by-case basis to maximize the return on investment for our oncology portfolio.
Share your needs with us:
Submit your input on products that are in short supply or challenging to handle for our R&D team to consider for pipeline development via Pipeline@ShorlaOncology.com
PIPELINE
Shorla Oncology has 4 FDA approved products on market along with an exciting pipeline in development.